GLP-1 receptor agonists (GLP-1 RAs) have reshaped the treatment of type 2 diabetes and obesity. But the next phase of GLP-1 therapy, and of incretin-based treatment more broadly, is likely to have implications that extend well beyond the approval of another weight-loss medication.
The category is becoming larger and more complex. Newer therapies include oral GLP-1 receptor agonists, dual and triple agonists, higher-dose formulations, longer-acting dosage forms, and drugs being studied across an expanding range of chronic conditions. At the same time, patients may obtain treatment through primary care physicians, specialists, telehealth platforms, and different pharmacy channels.
For pharmacists, this brings about some changes to the job. Dispensing and basic counseling remain important, but increasingly so do medication reconciliation, dose management, adherence support, side effect monitoring, and bridging the gaps among a fragmented treatment landscape. This article focuses on pharmacy practice in the United States, although many of the issues apply more widely.
The GLP-1 category is now more complex
“GLP-1” has become an umbrella term for medications that can differ considerably in their pharmacology.
Semaglutide is a GLP-1 receptor agonist, while tirzepatide targets both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. Investigational retatrutide goes further, targeting GIP, GLP-1, and glucagon receptors.
The GLP-1 landscape is also expanding beyond injectable medications. Oral formulations offer another route of administration, while research is ongoing involving different combinations and mechanisms intended to improve efficacy, tolerability, or metabolic outcomes.
That diversity creates opportunities for more individualized treatment, but it also creates additional complexity at the pharmacy counter.
Patients may understandably see these medications as variations of the same drug. Pharmacists need to recognize differences in indications, mechanisms, titration schedules, administration, adverse-effect profiles, and interactions; then communicate those differences in a way patients can understand.
The issue becomes especially important when a patient changes therapies. Moving between agents should not be treated as a simple milligram-for-milligram substitution. Pharmacists may need to establish which medication was previously used, the last dose administered, how long therapy has been interrupted, and whether re-titration is appropriate.
Expanding indications for GLP-1s
The advancement of incretin therapy is not limited to weight loss and blood sugar control.
Wegovy (semaglutide), for example, is indicated to reduce the risk of major adverse cardiovascular events in certain adults with established cardiovascular disease and obesity or overweight. [1] Zepbound (tirzepatide) became the first medication approved by the FDA for moderate-to-severe obstructive sleep apnea in adults with obesity. [2]
These expanding indications have practical implications for pharmacists. It becomes increasingly important to understand why the patient is receiving a particular medication rather than simply confirming that the patient is taking a GLP-1. The answer may affect therapeutic goals, monitoring, insurance coverage, and communication with other members of the healthcare team.
It also means that pharmacists may encounter these medications across a broader range of specialties. Endocrinologists, obesity-medicine specialists, and primary care clinicians are no longer the only prescribers who may be involved in incretin therapy.
As indications expand, the pharmacist can become an important continuity point between those different areas of care.
Counseling will need to become even more individualized
Patient counseling has always been important with GLP-1 therapy, particularly during initiation and dose increases. An expanding category of diverse medications can make standardized counseling inadequate.
Injection technique, storage, missed doses, and appropriate dose escalation remain fundamental for injectable therapies. Oral products introduce a different set of considerations, including administration requirements, adherence, and potential effects on concomitant oral medications.
Pharmacists should also prepare patients for what dose escalation actually means. The starting dose is generally intended to improve tolerability rather than deliver the full therapeutic effect immediately. Patients who expect rapid results may become discouraged, discontinue therapy prematurely, or attempt to increase the dose faster than recommended.
Counseling also provides an opportunity to distinguish expected adverse effects from symptoms requiring further evaluation.
Nausea, vomiting, diarrhea, and constipation are common concerns with incretin therapy. Persistent gastrointestinal symptoms, however, can contribute to dehydration and volume depletion. [3,4] Pharmacists should also be alert to symptoms potentially associated with more serious complications and know when referral to the prescriber or urgent evaluation is appropriate.
Medication reconciliation becomes more important
The growth of telehealth and specialized weight-management services has created additional pathways through which patients can receive GLP-1 therapy.
A patient may receive diabetes treatment from one clinician, obesity treatment through another service, and other medications through primary or specialty care. Unless those systems communicate effectively, no single clinician necessarily sees the complete medication picture.
That makes medication reconciliation particularly important.
Pharmacists can identify duplicate incretin therapy, outdated prescriptions remaining on medication lists, and concomitant medications that may require additional monitoring. Patients using insulin or insulin secretagogues, for example, may require closer assessment for hypoglycemia when incretin therapy is introduced or intensified.
Transitions also deserve special attention. Insurance formulary changes, adverse effects, shortages, and changes in treatment goals can all result in patients switching medications or experiencing gaps in therapy.
Before dispensing a restarted or replacement therapy, the pharmacist may need to clarify the patient’s previous product and dose, the length of the treatment interruption, and whether restarting at the previous dose is appropriate.
These interventions are relatively simple, but they can prevent avoidable medication errors.
Medication errors are a growing concern
The growing demand for GLP-1 therapy has introduced new medication-safety challenges, including differences in how products are dosed and administered. These risks are especially important when patients switch between manufacturer-supplied prefilled pens and compounded medications dispensed in multidose vials.
The FDA has emphasized that compounded drugs can present additional risks because they do not undergo the agency’s premarket review for safety, effectiveness, and quality. [5]
Dosing errors involving compounded injectable semaglutide have been reported, including cases in which patients administered five to 20 times the intended dose. Reported errors have resulted from confusion between milligrams, milliliters, and “units”; differences in product concentrations; and patients’ unfamiliarity with withdrawing medication from multidose vials. Some patients required medical attention or hospitalization. [6]
This is an area where pharmacist counseling can have an immediate impact. A patient receiving a vial and syringe requires different education than someone using a manufacturer-supplied prefilled pen. Pharmacists and other healthcare professionals should verify the product concentration, prescribed dose, appropriate syringe size, and the patient’s understanding of exactly how much medication to administer before treatment begins.
As the number and variety of incretin-based therapies continue to expand, clear dosing instructions and patient education will remain important medication-safety priorities. Pharmacists are well positioned to identify potential dosing discrepancies, reinforce correct administration technique, and make sure patients understand changes in dose or delivery system before they administer the medication.
Pharmacovigilance will become more important as GLP-1 use expands
Clinical trials cannot answer every safety question that emerges when a medication reaches a much larger and more diverse real-world population.
Pharmacists are among the healthcare professionals who have the most frequent contact with patients receiving chronic medications. That puts them in a valuable position to identify potential adverse drug events, medication errors, unusual product concerns, and patterns that warrant further investigation.
The scale of GLP-1 use makes this particularly relevant. Recognizing and reporting suspected adverse events and medication errors through appropriate pharmacovigilance channels is therefore another way pharmacists can contribute to the safe use of this rapidly expanding drug category.
Adherence is more than remembering a dose
New formulations may solve some adherence problems while creating others.
A patient who dislikes injections may prefer an oral medication. Another may find a once-weekly injection substantially easier than remembering a daily tablet. Cost, insurance coverage, gastrointestinal tolerability, and product availability may matter more to another patient than route of administration.
Pharmacists are particularly well positioned to recognize adherence problems before they become treatment failures.
Late refills, repeated gaps in therapy, confusion about titration, remaining on an introductory dose longer than intended, or skipping doses because of adverse effects can all provide useful information.
Rather than treating adherence as a binary question of whether the patient takes the medication or does not, the next generation of GLP-1 therapy will require pharmacists to identify the specific barrier and determine whether it can be addressed.
Pharmacists as a bridge across GLP-1 care
The future of incretin therapy will almost certainly offer patients more options. More options, however, do not necessarily simplify treatment.
A patient may eventually choose among injectable and oral therapies, single-, dual-, or triple-receptor approaches, different dosing schedules, and treatments selected partly based on comorbid conditions. Different specialists may prescribe those medications, and patients may obtain them through increasingly diverse healthcare channels.
The pharmacist occupies a distinctive position within that ecosystem.
Pharmacists can reconcile therapy across prescribers, identify duplication and dosing errors, manage treatment interruptions, reinforce appropriate titration, recognize adverse effects, support adherence, and help patients understand not only how to take their medication but why they are taking it.
The next generation of GLP-1 therapies will undoubtedly be defined by advances in pharmacology. Their real-world success, however, will also depend on whether healthcare systems can translate increasingly sophisticated treatments into safe, continuous, and understandable patient care.
For pharmacists, the opportunity is therefore bigger than dispensing the next GLP-1 prescription. It is becoming one of the professionals who connects all the pieces after that prescription is written.
Author Bio
